Early Access — free while we kick the tires
EdgarHawk

Mahkam Zanganeh

Co-Chief Executive Officer

Director Officer 10% Owner

Latest: CEO buying · June 2026

4 filings analyzed · 1 company · Latest 2026-06-12

Companies

Company Buys Sells Direction
Summit Therapeutics Inc. SMMT 7 0 Net buying

Activity

June 2026
2026-06-12 Summit Therapeutics Inc. SMMT Cluster
high
Buy
3,810,000 shares
$49,987,200
Significance 6/10

SMMT Co-CEO Zanganeh buys 3.81M shares at $13.12; stock down 28.4% in 30d, at -56.6% from 52-week high; cluster pattern with 2 other insiders in past 14 days.

Mahkam Zanganeh (Co-Chief Executive Officer) purchased 3,810,000 shares at $13.12 on 2026-06-12, increasing his holdings to 573,883,879 shares. This buy occurs amid sharply declining equity price: the stock is at $13.46 current price, down 28.4% over 30 days and 56.6% below its 52-week high of $30.98. At the same-ticker level, Zanganeh's prior four measurable trades at SMMT show mixed results (30-day range -12.2% to +20.8%; 90-day range -9.1% to +115.9%), with only 1 of 4 prior buys well-timed at the 90-day mark. The company reported $0.00 revenue (latest quarter) and net income of -$189,424,000 over the most recent full fiscal year, establishing an unprofitable operational baseline. Notably, 2 other insiders also bought within the past 14 days, creating a cluster buy pattern during a period of significant stock depreciation.

medium
Buy
100,000 shares
$1,460,000
Significance 5/10

Co-CEO Mahkam Zanganeh buys 100,000 SMMT shares at $14.60; stock down 52.1% from 52-week high despite $1.5M buy.

Mahkam Zanganeh, Co-Chief Executive Officer, purchased 100,000 shares at $14.60 on 2026-06-04, increasing his holdings from 25,724,474 to 25,824,474 shares. The stock has declined 52.1% from its 52-week high of $30.98 and is trading at $14.84, down 15.4% over the past 30 days. At the same ticker, his prior 5 buys show mixed outcomes: two trades showed 90-day gains of +115.9% and +115.3%, while the most recent buy on 2025-10-21 yielded a 90-day return of -9.1%. The company is unprofitable with a net income of $-189,424,000.00 for its most recent fiscal year and zero revenue in the latest quarter, presenting a high-risk fundamental backdrop against which this equity purchase occurs.

October 2025
high
Buy
26,680 shares
$499,983
Significance 7/10

Co-CEO Zanganeh Mahkam buys 26,680 shares of SMMT at $18.74; stock -48.9% from 52-week high, company unprofitable with $-231.8M net income.

Zanganeh Mahkam purchased 26,680 shares valued at $499,983.20 on 2025-10-21, extending a pattern of frequent accumulation at this ticker. Across his prior 5 trades at SMMT, three identical March 2024 buys each posted 90-day returns of +115.3% to +115.9%, and two September 2025 buys achieved 30-day returns of +18.2% and +20.8%; timing pattern shows 3 of 3 prior buys were well-timed at the 90-day mark. However, the current investment context is notably challenged: the stock trades -48.9% below its 52-week high of $36.70, has declined -34.6% over 90 days, and the company reported $0.00 revenue (latest quarter) with a net loss of $-231.8M annually. A 2-insider cluster buy within the past 14 days suggests coordinated confidence, yet absent profitable operations or revenue generation, the trade occurs against a materially weakened fundamental backdrop that distinguishes it from the company's prior high-valuation environment where his March and September purchases occurred.

September 2025
high
Buy
338,394 shares
$5,984,756
Significance 7/10

Co-CEO Zanganeh buys 338,394 shares at $17.69 avg (2 txns, $6.0M) as SMMT stock falls 27.6% in 30 days from 52-week high of $36.70.

Mahkam purchased 338,394 shares across two transactions on 2025-09-10 and 2025-09-11 at a blended average price of $17.69, investing $5,984,755.92 in the open market. The purchase occurs during a sharp decline—the stock has fallen 27.6% over the past 30 days and trades 49.3% below its 52-week high of $36.70. Mahkam's same-ticker history at SMMT shows 4 prior measurable buys executed in late March and December 2023, all of which generated positive 90-day returns ranging from 113.3% to 115.9%, demonstrating a pattern of well-timed accumulation at this ticker. The company remains unprofitable with a $-565,708,000.00 net loss in its most recent fiscal year and zero quarterly revenue, yet maintains a $13.8B market cap; this buying activity by the co-CEO during a period of weakness and amid fundamental challenges represents a material capital commitment that merits close investor observation.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access